Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Short-term Investments (2016 - 2017)

Adma Biologics' Short-term Investments history spans 3 years, with the latest figure at $1.5 million for Q4 2017.

  • For Q4 2017, Short-term Investments fell 72.17% year-over-year to $1.5 million; the TTM value through Dec 2017 reached $1.5 million, down 72.17%, while the annual FY2017 figure was $1.5 million, 72.17% down from the prior year.
  • Short-term Investments reached $1.5 million in Q4 2017 per ADMA's latest filing, up from $845389.0 in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $6.4 million in Q4 2015 to a low of $245000.0 in Q1 2017.
  • Average Short-term Investments over 3 years is $2.9 million, with a median of $1.5 million recorded in 2017.
  • Peak YoY movement for Short-term Investments: fell 15.36% in 2016, then plummeted 72.17% in 2017.
  • A 3-year view of Short-term Investments shows it stood at $6.4 million in 2015, then fell by 15.36% to $5.4 million in 2016, then tumbled by 72.17% to $1.5 million in 2017.
  • Per Business Quant, the three most recent readings for ADMA's Short-term Investments are $1.5 million (Q4 2017), $845389.0 (Q2 2017), and $245000.0 (Q1 2017).